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Screening newborn infants for inherited disorders has been effective in preventing mental
retardation, growth failure, and death from several metabolic disorders for more than two
decades. Technical advances have provided more screening tools for both genetic and non-
genetic conditions, and in the coming decades these techniques will be used not only to screen
newborns but to assess genetic risks in entire populations. The financial, legal, and ethical
issues which these activities raise must influence the development ofpublic policies in order to
reap the benefits promised. The conference published here was designed to address these
issues for health care practitioners, health policy planners, and public health professionals.
"New Technologies for Genetic and Newborn Screening: A Medical, Legal, and
Ethical Update," a symposium hosted by Yale University School of Medicine on
April 23, 1990, in New Haven, was designed to address four areas of importance in
the development and use ofnewborn and population screening forgenetic disorders:
Examples ofnew technologies, especially moleculargenetic tools
Implementation of new technology, especially laboratory, educational, and
counseling functions
Applications to non-genetic diseases such as infectious diseases, especially
public policy and ethical considerations
Medical-legal, ethical, and financial issues, including legal mandating ofscreen-
ing, confidentiality ofresults, responsibility forfollow-up, and stigmatization ofthose
screened
The papers in this symposium include two talksgiven at the beginning: the keynote
address, "Genetic Screening for the Next Decade: Application of Present and New
Technologies," by Edward McCabe, M.D., Ph.D., Baylor College of Medicine, and
"Legal Aspects of Genetic Information," by Lori Andrews, J.D., American Bar
Association. Rodney Hoff, D.Sc., New England Newborn Screening Program, dis-
cussed "Newborn Screening for Non-Genetic Disease." This discussion has been
published elsewhere [6] and is reviewed briefly in this paper.
Two panel discussions, "Implementation of New Technologies," chaired by Mar-
gretta R. Seashore, M.D., Yale University School of Medicine, and "Ethical, Legal,
and Financial Issues in Genetic Screening," chaired by Maurice J. Mahoney, M.D.,
Yale University School of Medicine, formed the rest of the symposium. Panel
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members included Edward McCabe, M.D., Ph.D., Baylor College of Medicine;
Edwin Naylor, M.D., University ofPittsburgh; Harvey Levy, M.D., Harvard Medical
School; Catherine Walsh-Vockley, M.S., Yale University School ofMedicine; Philip
Reilly, M.D., J.D., Eunice K. Shriver Center; Paul Billings, M.D., Harvard Univer-
sity; and Robert Pokorski, M.D., Lincoln National Life Insurance Company. Ques-
tions addressed to the panelists from the audience follow the summaries of each
panel discussion.
Nearly three decades have passed since the introduction ofnewborn screening for
inborn errors ofmetabolism, and the developments have been recently reviewed [1].
These programs were initially undertaken to detect infants affectedwith phenylketo-
nuria (PKU) in order to treat them and thus prevent the mental retardation
associated with PKU. Phenylketonuria had been recognized as an inherited cause of
mental retardation since Folling's original description in 1930, but it was not until
Woolf, Hudson, Bickel, and others applied a phenylalanine-restricted diet to treat
these infants that the need for identifying affected infants before they became
mentally damaged became critical. The development in 1962 ofabacterial inhibition
assay which would measure the concentration of phenylalanine in the blood of
newborn infants paved the wayfor early treatment ofthese infants. The methodwas
simple and employed a small amount ofblood soaked into filter paper and mailed to
a central laboratory. Screening programs based on this technology now exist in
laboratories around theworld. The programs have led to improved understanding of
the natural history, treatment, and genetics of important causes of infant morbidity
and mortality and mental retardation. Tests for an increasing number of disorders
have been applied. Most of these methods involve measurement of an excess or
deficiency ofa metabolite, a protein, or an enzyme.
Galactosemia, a disorder due to deficient metabolism of galactose (a component
ofthe sugar lactose present in milk) can be identified by measuring galactose in red
blood cells or by measuring the relevant enzymes, galactose-1-phosphate uridyl
transferase and galactokinase, in whole blood. Hypothyroidism, a condition due to
deficiency of thyroid hormone (and not usually inherited) can be detected by
measuring thyroid hormone in the blood. Both of these are disorders for which
newborn screening has been applied, using the Guthrie filter paper cards, in most
states throughout the United States as well as in Canada, Europe, and Japan. The
effect on mortality from galactosemia hasbeen dramatic, although there is still much
to be learned about optimal treatment to prevent learning disability. Newborn
screening for congenital hypothyroidism has been highly successful in preventing
long-term mental deficiency aswell as retardation ofgrowth and development.
Although the technology used in newborn screening for metabolic disorders has
been developed and refined for the last 30 years, the principles and goals embodied
in many of the basic ideas remain unchanged [2]. The major goal of newborn
screeningprograms is toprevent seriousmorbidityordeath from a treatable disorder
by identifying affected infants prior to the development of symptoms. This goal has
been expanded to include genetic counseling for families of affected infants. The
development of new technology for newborn screening must be in harmony with
thesewell-accepted goals.
A second application of genetic screening is heterozygote screening, designed to
identify individuals or couples at risk for having children with a serious genetic
disorder. Tay-Sachs disease was the first inherited condition for which wide-scale
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population screening for heterozygosity was performed. The identification of the
biochemical defect in this disorder and the demonstration [3] ofhalfnormal activity
of the defective enzyme, hexosaminidase A, in the serum of obligate carriers of the
Tay-Sachs disease gene made screening theoreticallypossible. The technologywhich
made enzyme analysis both automated and accurate turned this theoretical possibil-
ity into a reality. Tay-Sachs disease was an excellent model for population screening
for at least three reasons. The disorder is severe, it results in neurodevastation
leading to death, and it is untreatable. The population at highest risk iswell defined:
the Ashkenazic Jewish population. An intervention, accurate prenatal diagnosis of
affected fetuses, is available. Experience around theworld led to the development of
principles for heterozygote screening that can be applied to other disorders [4].
Advance planning, careful education of the target population, precise definition of
the population to be screened, and strict attention to technical matters are absolute
essentials in a heterozygote screening program. Not the least ofthe effort is spent in
education of the medical and public health professionals who will be asked to
support programs and to help in the education and follow-up of individuals tested.
The psychosocial risks of stigmatization and loss of self-esteem cannot be ignored.
Despite these caveats, the Tay-Sachs screening programs around the world have
been highly successful, and the incidence of Tay-Sachs disease in the Ashkenazic
population has decreased dramatically [5]. As the technology has been developed,
screening for heterozygosity for other inherited disorders such as sickle-cell anemia
and thalassemia has become possible, and screening populations for the common
cystic fibrosis mutations is nearly available. With the establishment of screening
programs for these disorders, the need to develop educational and counseling
methods to accompany the screening tests has become ever more obvious.
New technologies have created new opportunities to identify those at risk for the
development ofserious genetic disorders. These opportunities include the chance to
identify those at risk for a broad range of disorders and to offer intervention,
including treatment, prenatal diagnosis, and genetic counseling. In addition, physi-
cians, scientists, and others can learn more about the specific inherited conditions
and about the effect of genetic screening. Technical, ethical, and legal questions
raised by these developments are the subject ofthe papers by McCabe, Naylor, and
Andrews in this symposium.
Some of the techniques developed for screening in genetic screening programs
may be applicable to environmental screening-for example, newborn screening for
toxoplasmosis and human immunodeficiency virus infection [6]. The goals ofscreen-
ing for these non-genetic disorders are similar to the goals of screening for genetic
conditions; that is, intervention and counseling. Toxoplasmosis is an infectious
disease which leads to chorioretinitis and central nervous system damage when it is
contracted during fetal life. Transplacental transmission occurs in about 40 percent
ofinfantswhose mothers have active disease. Manyofthesecongenital infections are
clinically inapparent. Treatment with antimicrobial agents slows the reproduction of
the organism and ameliorates the disease in the infant. Hoff has reported [6] that
screening newborn blood samples from Guthrie cards using enzyme-linked immu-
nosorbent assay (ELISA) is effective in identifying infants who have antibodies to
this organism and who thus need further testing. Perinatal acquired immunodefi-
ciency syndrome (AIDS) due to human immunodeficiency virus (HIV) infection is
becoming a serious problem; as many as 30 percent of infants born to seropositive
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mothers may become infected. Because of problems of interpretation of serological
studies for HIV infection, methods using the polymerase chain reaction (PCR) to
identify the presence of HIV proviral DNA in the blood are being developed. The
extension of this technology to screening ofthe newborn infant isjust beginning [6].
Although satisfactory treatment for AIDS is not yet available, the screening proce-
dureswould facilitate both diagnosis and counseling for reproductive planning.
These newtechnologies may, however, cause serious repercussions throughout the
health care system. Theymaycontribute to the increasing cost ofmedical care before
the influence oftheir role in disease prevention is felt. Billings and Pokorski examine
the problems that increasing numbers ofpeople at known risks create for insurance
companies, health maintenance organizations, and other third-party payers. Billings
and Reilly point out that important privacy concerns must be addressed as such
persons are identified, and Pokorski and Reilly address the possible uses and misuses
of this information by others-for example, insurance companies. Legal issues,
including the need to set standards ofcare and the establishment ofa dutyto disclose
information, are reviewed by Andrews and Reilly. There will be imperfect tests, and
the balance between creating problems for those left with equivocal results and
producing good forthosewhose results are definitive willbe difficult to strike, apoint
covered by several ofthe participants in this symposium.
The questions raised by the audience attending this symposium range from
technical to financial. They demonstrate that dialogue within the community is not
only possible but that it is stimulating and useful. It must continue on formal and
informal levels ifthe goals noted at the beginning ofthis symposium are to be met. It
is hoped that this symposium and others like itwill arouse the interest ofthe medical
community and the public so that the promise of the new genetic technology will
become a reality.
SUMMARY
Technology for newborn and population screening for genetic conditions has
expanded rapidly over the last decade. The powerful new techniques of molecular
genetics promise to improve the health and well-being of infants yet unborn. The
development of specific molecular technology for the diagnosis of such genetic
disorders as sickle-cell anemia and cystic fibrosis will have major influence on the
medical and public health community. In order effectively to provide care and
guidance for their patients, physicians, nurses, and other health care providers will
need to be aware of the available tests, the crucial medical and counseling services,
and the ethical, legal, and financial implications which apply to newborn and
population screening. This symposium presents the current issues to health care
professionals, in order to establish dialogue among groups involved and to stimulate
community discussion.
The symposium was supported by a grant from the Department of Health and
Human Services, Bureau of Maternal and Child Health, and was organized by the
Screening Committee of the New England Regional Genetics Group (NERGG),
under the direction ofMargretta R. Seashore, M.D., and Catherine Walsh-Vockley,
M.S., of the Yale University Department of Human Genetics. The support and
participation ofthe Health Departments ofall the stateswhich are part ofNERGG,
the NERGG leadership, especially Merrill Henderson, M.S., Rudolph Hormuth,
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M.S., of the Genetics Services Branch, Bureau of Maternal and Child Health, and
Gertrude Bramley, M.D., Maternal and Child Health Medical Consultant to Region
1 ofthe Public Health Service, Department ofHealth and Human Services, are most
gratefully acknowledged.
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